Background: A limited number of studies have shown that cancer diagnosis plays a protective role in Alzheimer's disease. However, the effect of the cancer diagnosis on general cognitive function/cognitive decline has not been previously examined. The aim of this study was to investigate the relationship between cancer diagnosis and cognitive function and mild cognitive impairment/disorders (MCI/MCD), adjusting for cancer treatments. Methods: These data were drawn from the Personality and Total Health (PATH) Through Life Study, a population-based Australian cohort study. A total of 2,547 participants (age range 60-66 years; 48.4% women) who answered cancer-related questions were included in analyses. Random effects linear and logistic models were used to analyze 8-year follow-up data. Results: Participants who were diagnosed with cancer at or prior to baseline (n = 166) had higher levels of physical conditions and depression compared with those who received cancer diagnoses during follow-ups (n = 346) and those who reported no cancer history (n = 2,035). A main effect suggested an improvement in processing speed (p < .01), working memory (p < .05), and simple reaction time (p < .05) for those who received the cancer diagnosis after baseline when compared with those without a cancer diagnosis. However, these group differences were no longer significant when adjusted for cancer treatments. Those with a cancer diagnosis at or prior to baseline reported poorer processing speed when compared with those without a cancer diagnosis, even after adjusting for the treatments. Conclusions: A cancer diagnosis alone did not play a protective role for cognitive function and cognitive impairment in this population of older community-living individuals.
The long-term impact of cancer on neurocognitive function is an issue relevant to large numbers of aging adults, their physicians, and families. The lifetime prevalence of cancer at any site for men is 43.31% and for women is 37.81% (1) . These rates are as high as or higher than the prevalence of many other established risk factors for dementia such as smoking, hypertension, high cholesterol, and obesity. Hence, there is a strong need to establish how cancer diagnosis influences the risk of dementia. It is estimated that in the United States alone there are approximately 10.4 million cancer survivors aged 60 and older in 2014 (2) . Moreover, a majority of cancer survivors would have experienced surgery and/or other types of treatments such as chemotherapy and radiotherapy.
Recent studies have demonstrated an inverse association between cancer and Alzheimer's disease (AD) suggesting that cancer patients may have a reduced risk of AD (3) (4) (5) . One longitudinal study followed more than 1,000 participants with and without a history of cancer who were aged 65 and older and free of dementia at the baseline assessment (1986) (1987) (1988) (1989) (1990) (4) . Over a mean follow-up of 10 years, cancer survivors had a lower risk of probable AD (hazard ratio = 0.67, 95% confidence interval = 0.47-0.97). This was confirmed by another report from an Italian registry study that linked cancer and dementia diagnoses using medical records and compared these with expected rates of AD using population-based statistics (not control participants; risk ratio [RR] = 0.65, 95% confidence interval = 0.56-0.76) (5) . Ma and colleagues' meta-analysis study also suggested that the patients with a history of cancer had a 37% decreased risk of AD (RR = 0.63, 95% confidence interval = 0.56-0.72) (6) . However, no association between cancer and vascular dementia was detected (7) .
These previous studies had a number of methodological limitations, which reduced the weight that can be placed on their findings including survival bias, accuracy of medical records in data linkage studies, and wide confidence intervals around prevalence rates for dementia used in the Italian study (ie, the study did not use a control group). Additionally, effects of cancer treatments as covariates were not examined even though a majority of cancer survivors would have experienced surgery and/or other types of treatments such as chemotherapy and radiotherapy. Lastly, these studies mainly examined the relationship between cancer and AD but did not investigate other types of dementia, with the exception of Roe's study (7) . The effect of a cancer diagnosis on general cognitive function/cognitive decline has also not been examined. The current study, therefore, aims to investigate the relationship between cancer diagnosis and cognitive function/impairment, adjusting for cancer treatments in a population-based Australian cohort study, the Personality and Total Health (PATH) Through Life Project.
Methods

Participants
The sample was drawn from the PATH Through Life Project, a large community survey of adults from Canberra and the neighboring town of Queanbeyan, New South Wales, Australia. The PATH project was established to evaluate the course of mental health, cognition, and substance use across the adult lifespan and is being undertaken by the Centre for Research on Ageing, Health and Wellbeing at the Australian National University (8) . The sample aged 60-64 years at baseline was recruited from the electoral roll as voting is compulsory for Australian citizens. At Wave 1 (baseline), 2,551 participants were assessed. Of those, 2,222 participants were reassessed 4 years later at Wave 2, and 1,973 were reassessed after 8 years at Wave 3. Participants were excluded from all analyses if they did not complete questionnaires on cancer history, leaving a sample of 2,547. This sample consisted of 2,035 participants without a history of cancer, 166 participants with cancer diagnoses at or prior to baseline, and 346 with cancer diagnoses during the 8-year follow-up.
Participants were assessed in their home or at the Australian National University, and most of the interview was self-completed on a laptop computer. A trained interviewer administered the cognitive tests and physical tests. The PATH Through Life Project has ethical approval from the Australian National University's Human Research Ethics Committee and all participants provided written informed consent.
Measures
History of cancer and cancer treatments At each wave, participants were asked if they had ever been diagnosed with cancer (yes/no). At Wave 3, a detailed questionnaire regarding cancer diagnosis and treatments was administered providing information on cancer type including leukemia; melanoma; and lung, breast, uterus, ovary, stomach, colon, small bowel, lymph nodes, and other cancers. For each type of cancer, data were collected on the type of treatment received including surgery (yes/no), radiation (yes/no), and chemotherapy (yes/no). Non-melanomatous skin cancers were excluded from analyses. To establish the reliability of the self-report cancer diagnoses, the distribution of the total number of cancer diagnoses for the cohort was compared with de-identified data obtained from the Australian National Cancer registry. There was no difference in the frequency of cancer reported in the cohort with that recorded on official records χ 2 (1) = 2.158, p = .142.
Cognition
Cognitive function was assessed using the following tasks at each wave. Spot-the-Word was used to assess verbal ability. Participants choose the real words from 60 pairs of words and nonsense words (9) . Processing speed was assessed with the Symbol-Digit Modalities Test (SDMT) (10) , which requires participants to press a key indicating whether the digit corresponding to a specific symbol is correctly matched or not and to complete as many symbol-digit pairs as possible in 90 seconds. Episodic memory was assessed with the first trial of the California Verbal Learning Test (11) , which involves recalling a list of 16 nouns. A distractor task (grip strength) was administered between the immediate and delayed recall tests. Working memory was assessed using the Digits Backwards subtest of the Wechsler Memory Scale (12) . Simple and choice reaction time (SRT and CRT) were administered using a small box, with left and right buttons to be pressed with the index fingers on the appearance of a light. Mean SRT was the average of four blocks of 20 trials. Mean CRT was the average of two blocks of 20 trials. Lower scores in SRT and CRT represent faster reaction time.
In addition to the cognitive measures above, mild cognitive impairment (MCI) and mild cognitive disorders (MCD) were also assessed. The clinical assessments procedures and criteria have been described elsewhere (8) . Briefly, a cognitive battery was used to screen participants into a substudy on neurocognitive disorders including MCI and dementia. Participants were selected for a clinical assessment if they did not meet the predetermined cutoff score for selected tests. The clinical assessment involved a Structured Clinical Assessment for Dementia, a neuropsychological assessment, and the Clinical Dementia Rating Scale. Diagnoses were formulated from clinical checklists, data from the neuropsychological assessment, and neuropsychological and medical history. The classification of any MCD included MCI, ageassociated memory impairment, age-associated cognitive decline, mild neurocognitive disorder, and other cognitive disorders.
Covariates
Years of education were computed based on self-report. Smoking status was derived from questions on current and past smoking habits. Depression was measured with the PRIME-MD Patient Health Questionnaire (PHQ), which asks about DSM-IV major depressive symptoms in the past 2 weeks (13). This questionnaire was scored to give a continuous scale from 0 to 27. The SF-12 physical health (PCS-12) was used to measure physical disability using the RAND-12 scoring (14, 15) .
Analysis
Baseline characteristics were compared with analysis of variance for continuous variables and χ 2 tests for categorical variables. Those with cancer at or prior to baseline and those with a cancer diagnosis during the follow-up were compared against those who were not diagnosed with cancer up until and including the third observation (8 years of follow-up).
Random effects linear models with random participant intercepts, cancer group (reference group: no cancer) as a factor, and waves of observation as a time of measurement (reference group: baseline observation) were used to evaluate changes in cognitive function over an 8-year follow-up. Random effects logistic models were used to assess changes in MCI and MCD. Model 1 examined the effects of cancer history and time, and Model 2 was further adjusted for cancer treatments (chemotherapy, radiotherapy, and surgery).
The association between cancer survival status and mortality until Wave 3 was assessed using Cox proportional hazards regression models. Analyses were conducted in IBM SPSS statistics 22 and STATA version 14.1. Table 1 shows descriptive characteristics at baseline observation for those who reported a history of cancer at or prior to Wave 1 (baseline; n = 166), those who reported having cancer during the 8-year followup (n = 346), and those who reported no history of cancer (n = 2,035). Those with a history of cancer were significantly more likely to be men (p < .001) than those without a cancer history. Those who developed cancer during the follow-up had higher levels of education (p < .05) and were less likely to be current smokers (p < .05) than those with cancer at or prior to Wave 1 and those without a cancer history. Participants with cancer at or prior to baseline had higher levels of depression (p < .005), more hypertension (p < .005), physical disability (p < .001), and heart conditions (p < .001) compared with those who did not.
Results
Melanoma (n = 85, 16.6%), colorectal (n = 44, 8.6%), breast (n = 84, 16.4%), and prostate (n = 104, 20.3%) cancer were the most prevalent cancer types among those with a cancer history. This reflected the four most common types of cancer in Australia (16 
Cognitive Function Over 8 years
The cognitive function scores for each cancer group are shown in Supplementary Table 1. Table 2 reports the results of analyses of longitudinal change in cognitive function by time and cancer status. A main effect of time indicated a decline in processing speed, SRT, and CRT from baseline to Wave 2, and baseline to Wave 3. Results also showed an improvement in delayed recall, working memory, and verbal ability from baseline to Wave 2, a decline in immediate and delayed recall from baseline to Wave 3, and an improvement in verbal ability from baseline to Wave 3.
There were no significant associations between cancer diagnoses and MCI or MCD (Table 3) , except for MCD where a main effect of time was found at Wave 3, indicating a greater risk of developing MCD over 8 years follow-up.
Time Since diagnosis
A main effect for the cancer group suggested a decline in processing speed for those who had cancer at or prior to Wave 1 and an improvement in processing speed for those who were diagnosed with cancer after Wave 1 when compared with those without a cancer diagnosis. However, the effect of a cancer diagnosis after Wave 1 failed to reach significance when adjusted for cancer treatments (Model 2). Acquiring a cancer diagnosis after Wave 1 was also associated with improved working memory, verbal ability, and SRT compared with those without a cancer diagnosis. However, these effects also disappeared after adjusting for treatments (Model 2). There were no significant associations between cancer diagnosis and CRT and episodic memory.
Cancer Diagnosis and Cognitive Function Over 8 Years
A cancer group × time interaction indicated a significant decline in processing speed for those with cancer at or prior to Wave 1, at the Notes: W1 = Wave 1; W2 = Wave 2; W3 = Wave 3. Models estimated using standardized z scores for comparability across cognitive function. Model 2 adjusted for cancer treatments (chemotherapy, radiotherapy, and surgery). Cancer at or prior to W1, n = 166 (6.5%); cancer after W1, n = 346 (13.6%); no cancer, n = 2,035 (79.9%).
*p < .05, **p < .01, ***p < .005, ****p < .001.
4-year follow-up (Wave 2)
. A significant improvement in SRT was observed for those with cancer at or prior to Wave 1, at the 8-year follow-up (Wave 3). These effects remained significant after adjusting for cancer treatments.
Impact of Mortality on Results
To assess whether the cancer-cognition association is underestimated because of premature mortality among cancer survivors, we examined the association between cancer status, at both Wave 1 or at any time over the three waves, and mortality during the follow-ups until Wave 3 while controlling for age, gender, marital status, and education. The mortality risk of cancer survivors was not higher at any time over the three waves compared with that of people without cancer (Figure 1 ).
Discussion
This study reports the association between cancer diagnosis and changes in cognitive function and cognitive impairment from a population-based Australian cohort study, the PATH Through Life Project. Our results are in partial agreement with previous study findings where certain domains of cognitive function were affected by cancer/cancer treatments (4-6). This could be because previous studies dismissed the effect of treatment in their models, or did not consider the time of diagnosis. The effect of chemotherapy on cognitive function was found in a previous study (17) , where domains of memory, processing speed, and executive function were negatively associated with receiving chemotherapy. This was similar to what the current research has found in terms of domains of cognitive function affected by cancer although the current research findings were different in terms of the direction of associations. The results from a main effect of cancer diagnosis suggest that cancer diagnosis may be associated with a "protective" effect for a number of domains of cognitive functions, including processing speed, working memory, verbal ability, and SRT. However, this protective effect of cancer history varied with the time of diagnosis as the protective effects were found only with those with cancer diagnosis after baseline. Our results also suggested a decline in processing speed for those who had cancer at or prior to baseline but an improvement for those who were diagnosed with cancer after the baseline. The current study therefore partially supports the negative associations found between cancer/chemotherapy and cognitive function in previous studies (18, 19) . Three explanations can be offered for these paradoxical findings. One explanation points to an effect of participants' mean assessment age as some previous studies were conducted using much younger (mean age of late 40s to early 50s) samples than the current study. Another explanation relates to the study design used in previous studies, whether cross-sectional or longitudinal. More recent studies such as Williams and colleagues (20) , which used a nationally representative sample of older U.S. adults (aged 60 and older), indicated that cancer survivors performed worse on an objective test of processing speed, attention, executive function, learning, and working memory. However, this study used a cross-sectional design, and therefore, any changes that might have occurred over time were not examined. In contrast, a recent meta-analysis based on longitudinal studies, and therefore more comparable with the present findings, reported significant improvement in most cognitive functions (immediate recall, visual delayed memory, focused attention, capacity of attention, and verbal abilities) (21) . The last explanation may involve the age at cancer diagnosis/treatment. Notes: BMI = body mass index; MCD = mild cognitive Disorder; MCI = mild cognitive impairment; W1 = Wave 1; W2 = Wave 2; W3 = Wave 3. Odds ratio (with standard error) from random effects logistic regression (reference group no cancer). Model adjusted for age, sex, education, smoke status, diabetes, BMI, and physical disability at baseline. Cancer at or prior to W1, n = 166 (6.5%); cancer after W1, n = 346 (13.6%); no cancer, n = 2,035 (79.9%).
*p < .01, **p < .005. Koppleman and colleagues (22) found that breast cancer survivors treated with chemotherapy more than 20 years before assessment performed worse, on average, on neuropsychological tests than random population controls. However, in this sample, the mean age at cancer diagnosis was 42.9 years, suggesting that diagnosis in middle age might be linked with a decline in processing speed as suggested in the current study. Moreover, our results suggest that it is likely that cancer diagnosis alone does not play a protective role for cognitive function and cognitive impairment in this population of older community-living individuals as the protective effects disappeared when adjusted for treatments. It was also suggested that the time since cancer diagnosis may be important in determining the long-term effect of cancer on cognitive aging shown in cancer group × time associations. We are not aware of any other cohort studies reporting longitudinal data on changes in cognitive function therefore, we are unable to compare our findings to other similar research. However, our results indicate that those who developed cancer in later life (after Wave 1) appear to have faster decline than those who developed cancer earlier (at baseline or before). Furthermore, developing cancer, regardless of the time of the diagnosis, did not influence whether they developed MCI or MCD. In addition, we did not find widespread effects of cancer on cognitive function. Current and previous research demonstrated that not all domains of cognitive functions are affected by cancer diagnosis or cancer treatments.
Our study has several strengths. We used a large populationbased sample including three waves of data. Therefore, we could evaluate the changes in cognitive function and incident MCI/ MCD. Another strength of the study is that unlike previous investigations which focused on AD or other dementia, we examined general cognitive function in relation to cancer diagnosis. To our knowledge, this study is the first population-based longitudinal study to examine the effect of a cancer diagnosis on general cognitive function and impairment while adjusting for cancer treatments. This study is novel in suggesting that the previously found protective effects associated with cancer survivors could be due to other factors such as treatments they have received rather than cancer diagnosis alone.
There are some limitations that need to be considered. Information on how advanced the cancer was (stage of cancer) was not available as it is likely that the cancer stage is associated with whether the person had to receive the cancer treatment or type and duration of treatment they should receive. Moreover, our results are limited by the small number of participants reporting cancer diagnosis compared with those without. The narrow age range of our cohort reduces the impact of age differences confounding results but also limits the generalizability of findings. Our diagnoses were also self-reported and participants with severe disability from cancer diagnosis may have been lost to attrition. However, as we could obtain the death data for participants for all three waves, we were able to assess the association between cancer survival status and mortality, making sure the cancer-cognition association was not due to premature mortality among cancer survivors.
Publication of associations between cognitive change and cancer diagnosis from other cohort studies with varying lengths of followup will allow for these findings to be pooled across a greater number of participants and robust estimates to be established through metaanalyses. A future study examining a possible explanation of cognitive decline, for example, type and length of treatment, to investigate if they have mediator or moderator effects.
In conclusion, our study suggests that cancer diagnosis alone may not play a protective role for cognitive function or cognitive impairment and highlight the need for the effect of cancer treatment on dementia and cognitive function to be investigated in conjunction with a cancer diagnosis. 
Supplementary Material
